Naurex Inc.
This article was originally published in Start Up
Executive Summary
Naurex Inc. is developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the NMDA receptor in a safe way glycinesite functional partial agonists, which only partially activate NMDAR, versus fully antagonizing it as ketamine does. There is evidence that such agents can benefit CNS disorders like depression without the typical bad side effects. The injectable Naurex medication could prove valuable for treatment-refractory patients in the inpatient setting.